The global artificial heart lung machine market is expected to develop at a CAGR of XX% starting in 2024, reaching USD XX million by 2024 and USD YY million by 2031. North America currently dominates the market due to the high prevalence of cardiovascular illnesses, sophisticated healthcare infrastructure, favourable reimbursement regulations, and the presence of important industry participants. The rising frequency of cardiovascular disorders, the increasing number of cardiac surgeries, technological improvements in artificial heartlung machines, and the growing elderly population all contribute to market expansion. However, the high cost of artificial heart-lung machines and the danger of complications associated with their usage may limit market expansion to some extent.
Technological advancements in artificial heart lung machines
Artificial heartlung machines have undergone significant technological improvements in recent years, improving their efficiency, safety, and ease of use. For example, the use of centrifugal pumps has lowered the danger of blood injury and haemolysis when compared to classic roller pumps. Similarly, the development of portable and compact heart-lung machines has enabled their usage in a broader range of settings, such as ambulatory surgery centres and mobile cardiac units. LivaNova PLC will release the S5 Revolution centrifugal pump and heart lung machine in 2021, with increased safety features and customisable settings for optimal patient management.
Rising Incidence of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the major cause of death globally, accounting for around 31% of all deaths. The increased incidence of CVDs, particularly in developing nations, is predicted to drive up demand for artificial heart and lung devices. The World Health Organisation (WHO) estimates that the number of deaths from CVDs would reach 23.6 million by 2030. Unhealthy lifestyles, obesity, smoking, and an ageing population are all contributing to an increase in the prevalence of cardiovascular diseases.
High Cost of Artificial Heart Lung Machines
Artificial heartlung machines are very complicated and expensive medical devices, costing between $150,000 and $300,000 per unit. The high cost of this equipment may limit its use. especially in price-sensitive markets and small healthcare facilities. Furthermore, the use of artificial heartlung machines necessitates specialised training and competent people, increasing the entire cost of care. The expensive cost of artificial heart and lung machines may impede market expansion, particularly in developing nations with limited healthcare resources.
Double roller pump segment to witness highest growth
The double roller pump category is predicted to experience the most growth over the projection period. Double roller pumps provide various advantages over single roller pumps, including increased blood flow rates, less haemolysis, and improved pressure management. They are especially useful for difficult heart operations and long-term procedures. Medtronic plc announced the Bio-Medicus NextGen Double Roller Blood Pump in 2021, with enhanced occlusion and convenience of operation over its predecessor.
The single roller pump category dominated the artificial heart lung machine market in 2022. Single-roller pumps are popular in cardiac procedures due to their simplicity, dependability, and inexpensive cost. They are especially beneficial in paediatric and neonatal operations, which require modest blood flow rates. However, growth in this area is likely to be slower than in the double roller pump segment due to increased usage of advanced technology.
North America dominates the Global Artificial Heart Lung Machine Market
North America dominated the global artificial heart lung machine market in 2023, and this trend is likely to continue during the forecast period. The region's high prevalence of cardiovascular illnesses, well-established healthcare infrastructure, favourable reimbursement regulations, and presence of important market players all contribute to its large market share. According to the American Heart Association (AHA), cardiovascular disease is the top cause of mortality in the United States, responsible for 868,662 deaths in 2020.
The Asia-Pacific region is predicted to see the fastest growth over the forecast period, owing to factors such as rising cardiovascular disease prevalence, increased healthcare expenditure, improved healthcare infrastructure, and increased medical tourism. The artificial heart lung machine market in China is expected to develop at a CAGR of more than 10% over the forecast period, driven by a high patient population and an increase in the number of cardiac procedures.
The global artificial heart and lung machine market is moderately consolidated, with a few prominent manufacturers holding a sizable market share. To increase their market position, these companies are prioritising product innovation, strategic collaborations, and regional expansion.
In 2022, LivaNova PLC had the biggest market share, trailing Medtronic plc, Getinge AB, Terumo Corporation, and Braile Biomédica. LivaNova PLC's flagship product is the S5 heart-lung machine, which is widely used in cardiac surgery around the world. In January 2022, the business gained FDA 510(k) clearance for its B-Capta, an in-line blood-gas monitoring device that is integrated into the S5 heart lung machine.
Medtronic plc provides a variety of heart and lung equipment, including the Bio-Console 560 and Bio-Medicus NextGen Blood Pump. In September 2021, the business purchased Affera, Inc., a medical technology company that specialises in treating cardiac arrhythmias. Other significant market players include Xenios AG (bought by Fresenius Medical Care), Cardinal Health, Soma Technology, Jarvik Heart, Inc., and Tianjin Medical.
The artificial heart lung machine market is expected to rise steadily in the coming years, owing to increased incidences of cardiovascular disorders, technical advancements, and an increase in the number of cardiac surgeries performed worldwide. The COVID-19 pandemic had a mixed effect on the market, with a brief drop in elective procedures offset by increased demand for ECMO in severe COVID-19 cases.
Double-roller pumps are predicted to expand the most, but single-roller pumps will continue to have the largest market share. North America will remain the largest market, with Asia-Pacific being the fastest-growing area. Technological advancements aimed at increasing the safety, efficiency, and portability of heart lung machines will be critical in driving market expansion. Strategic alliances between manufacturers and healthcare providers will also play an important role in broadening market reach.
Factors such as the high cost of heart-lung devices and a shortage of experienced specialists may impede market expansion, especially in emerging nations. Nonetheless, the expanding adoption of heart-lung machines in ambulatory surgical centres, as well as the rising demand for minimally invasive cardiac procedures, present considerable development prospects for market players.
LivaNova PLC
Medtronic plc
Getinge AB
Terumo Corporation
Braile Biomédica
Xenios AG (Fresenius Medical Care)
Cardinal Health
Soma Technology
Jarvik Heart, Inc.
Tianjin Medical
In January 2022, LivaNova PLC gained FDA 510(k) clearance for its B-Capta, an in-line blood-gas monitoring device integrated into the S5 heart-lung machines.
Medtronic plc bought Affera, Inc., a medical technology business that specialises in treating cardiac arrhythmias, in September of 2021.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking: Key Players
3.3. Market Share Analysis: Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)*
5. COMPANY PROFILES
5.1. LivaNova PLC
5.2. Medtronic plc
5.3. Getinge AB
5.4. Terumo Corporation
5.5. Braile Biomédica
5.6. Xenios AG (Fresenius Medical Care)
5.7. Cardinal Health
5.8. Soma Technology
5.9. Jarvik Heart, Inc.
5.10. Tianjin Medical *LIST NOT EXHAUSTIVE
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Technological Advancements in Artificial Heart Lung Machines
6.1.2. Growing Adoption of Minimally Invasive Cardiac Surgeries
6.1.3. Increasing Use of Artificial Heart Lung Machines in Ambulatory Surgical Centres
6.2. Market Drivers
6.2.1. Rising Incidence of Cardiovascular Diseases
6.2.2. Growing Number of Cardiac Surgeries
6.2.3. Ageing Population and Increasing Life Expectancy
6.3. Market Restraints
6.3.1. High Cost of Artificial Heart Lung Machines
6.3.2. Risk of Complications Associated with Artificial Heart Lung Machines
6.3.3. Shortage of Skilled Professionals
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (% (2020-2031)
7.1. Single Roller Pump
7.1.1. S3 Roller Pump
7.1.2. S5 Roller Pump
7.1.3. Others
7.2. Double Roller Pump
7.2.1. S7 Double Roller Pump
7.2.2. Bio-Medicus NextGen
7.2.3. Others
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (% (2020-2031)
8.1. Cardiac Surgery
8.1.1. Coronary Artery Bypass Grafting (CABG)
8.1.2. Valve Replacement/Repair
8.1.3. Others
8.2. Lung Transplant Operation
8.3. Acute Respiratory Failure Treatment
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (% 2020-2031)
9.1. Hospitals
9.2. Ambulatory Surgical Centres
9.3. Speciality Clinics
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (% (2020-2031)*
10.1. North America
10.1.1. U.S.
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of Latin America
10.5. Middle East & Africa
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of MEA
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (% (2020-2031)
By Type:
Single Roller Pum
Double Roller Pum
By Application:
Cardiac Surger
Lung transplant operation
Acute Respiratory Failure Treatment
By End User:
Hospitals
Ambulatory Surgical Centres
Speciality Clinics
By Region:
North Americ
Asia-Pacifi
Latin Americ
Middle East & Afric
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
